Morrissey Michael James, an insider at Incyte Corp (INCY), sold 85,005 shares of the company on December 15, 2025, at a price of $97.42 per share. The total transaction value reached $8.28 million. Following this sale, Morrissey retains 85,005 shares of Incyte.
Incyte Corp is a biopharmaceutical company engaged in the discovery, development, and commercialization of proprietary therapeutics. The company operates in two therapeutic areas: Hematology/Oncology and Inflammation and Autoimmunity. Its hematology and oncology franchise includes six products, such as JAKAFI (ruxolitinib) and MONJUVI (tafasitamab-cxix), among others. As of November 20, 2025, Incyte boasts a market capitalization of $20.2 billion, a P/E ratio of 17.00, and an EPS of 5.91.
The move underscores the ongoing transparency required in insider trading, as such transactions must be reported to the SEC. While this sale may attract attention, it is essential for investors to consider insider activity within a broader context, examining patterns across multiple insiders and time periods rather than isolated transactions. Incyte's upcoming earnings report is scheduled for April 27, 2026, with an EPS estimate of $1.71 and revenue expected to reach $1.3 billion.